Simulations Plus News

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil	Trading-Depot	Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Trading-Depot

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

05.01.21	Simulations Plus Enters New Funded Collaboration to Enhance Top-Rated GastroPlus® ACAT™ Model for Oral Absorption of Peptides (Businesswire)
04.01.21	Simulations Plus Sets Date for First Quarter Fiscal Year 2021 Earnings Release and Conference Call (Businesswire)
16.12.20	Simulations Plus Publishes its Inaugural Environmental, Social and Governance (ESG) Report (Businesswire)
03.12.20	DILIsym Services Presents Important DILIsym and NAFLDsym Software Applications at the Virtual AASLD Liver Meeting (Businesswire)
01.12.20	Simulations Plus Names Industry Veteran Will Frederick as Chief Financial Officer (Businesswire)
16.11.20	Simulations Plus Reports FY2020 and Fourth Quarter FY2020 Financial Results (Businesswire)
10.11.20	DILIsym Plays Critical Role in Submission to State of California for Common Analgesic Carcinogenicity Risk Assessment (Businesswire)
09.11.20	Simulations Plus Sets Date for 4th Quarter and Fiscal Year 2020 Earnings Release and Conference Call (Businesswire)
05.11.20	Simulations Plus to Participate in the Credit Suisse Virtual Healthcare Conference (Businesswire)
03.11.20	Lixoft Expands MonolixSuite™ in Version 2020R1 (Businesswire)
27.10.20	First Approved Cancer Treatment for TGCT Included DILIsym Simulations in FDA Review (Businesswire)
20.10.20	Simulations Plus Releases GastroPlus® Version 9.8 (Businesswire)
13.10.20	Simulations Plus Announces Quarterly Cash Dividend of $0.06 per Share (Businesswire)
13.10.20	Simulations Plus Teams Up with the University of Health Sciences and Pharmacy in St. Louis to Secure New Grant Award from the U.S. FDA (Businesswire)
29.09.20	Simulations Plus Extends Partnership with Large Pharmaceutical Company to Further Expand High-Throughput PBPK Capabilities in ADMET Predictor® (Businesswire)
22.09.20	Simulations Plus Partners with Large Pharmaceutical Company to Validate AI-Driven Drug Design Capabilities in ADMET Predictor® (Businesswire)
15.09.20	Simulations Plus Releases ADMET Predictor® Version 10.0 (APX) (Businesswire)
02.09.20	FDA Review of Approved Drug, Ubrogepant, Included DILIsym Simulations (Businesswire)
31.08.20	Simulations Plus to Present at the LD 500 Virtual Conference (Businesswire)
10.08.20	Simulations Plus Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares (Businesswire)
06.08.20	Simulations Plus Announces Pricing of $100 Million Underwritten Offering of Common Stock (Businesswire)
04.08.20	Simulations Plus Announces Proposed Underwritten Public Offering (Businesswire)
09.07.20	After Market Hours: Spartan Energy, PriceSmart, Simulations Plus Gain; WD-40, Franklin Covey Slip (RTTNews)
09.07.20	Simulations Plus Reports Third Quarter FY2020 Financial Results (Businesswire)
02.07.20	Simulations Plus Sets Date for 3rd Quarter 2020 Earnings Release and Conference Call (Businesswire)
29.05.20	ABIO Jumps On Joining COVID-19 Drug Fray, GMAB Hits Trial Goal, IMRA On Watch (RTTNews)
28.05.20	Simulations Plus Receives New Grant Award from the FDA (Businesswire)
21.05.20	Simulations Plus to Present at 17th Annual Craig-Hallum Institutional Investor Conference (Businesswire)
13.05.20	Simulations Plus to Present at 15th Annual Needham Virtual Technology & Media Conference (Businesswire)
02.04.20	Simulations Plus Sets Date for 2nd Quarter 2020 Earnings Release and Conference Call (Businesswire)
02.04.20	Simulations Plus Acquires Lixoft, Expanding Modeling Software Offerings and Broadening Presence in Europe (Businesswire)
26.03.20	Simulations Plus Offers Rapid Response COVID-19 Research Initiative (Businesswire)
18.03.20	Sandra Suarez-Sharp Joins Simulations Plus to Lead Regulatory Strategies Team (Businesswire)
04.02.20	DILIsym Services Partners with Large Pharmaceutical Company to Begin QSP Model Development for Heart Failure (Businesswire)
13.01.20	Simulations Plus to Present at the 22nd Annual Needham Growth Conference (Businesswire)
09.01.20	Simulations Plus Reports Record First Quarter FY2020 Financial Results (Businesswire)
03.01.20	Simulations Plus Sets Date for First Quarter Fiscal Year 2020 Earnings Release and Conference Call (Businesswire)
05.12.19	Simulations Plus Partners with Bayer AG to Develop New Cheminformatics Capabilities in ADMET Predictor (Businesswire)
21.11.19	Simulations Plus Partners with Large Pharmaceutical Company to Add New Capabilities to PKPlus (Businesswire)
14.11.19	Simulations Plus Partners with Large Pharmaceutical Company to Enhance the Mechanistic Oral Absorption (ACAT) Model in GastroPlus (Businesswire)
13.11.19	Simulations Plus Reports FY2019 and Fourth Quarter FY2019 Financial Results (Businesswire)
06.11.19	Simulations Plus Sets Date for 4th Quarter and Fiscal Year 2019 Earnings Release and Conference Call (Businesswire)
29.10.19	Simulations Plus to Support Development of Radiation Countermeasure via New QSP Platform (RADAsym) and Pharmacometrics Modeling (Businesswire)
17.10.19	Simulations Plus Partners with Large Pharmaceutical Company to Develop the Virtual Bioequivalence Trial Simulator™ Module (Businesswire)
14.10.19	Simulations Plus Announces Quarterly Cash Dividend of $0.06 per Share (Businesswire)
02.10.19	Simulations Plus Announces Leadership Changes at Cognigen (Businesswire)
04.09.19	Simulations Plus Partners with Clinical-Stage Biotech Company to Develop Novel Dosing Models (Businesswire)
16.07.19	Simulations Plus Enters into New Research Collaboration Agreement with the FDA (Businesswire)
10.07.19	Simulations Plus Reports Third Quarter FY2019 Financial Results (Businesswire)
09.07.19	Simulations Plus Upgrades PKPlus™ (Businesswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Logitech Intl	65.64	3.60 %	K V
Part Grp Hldg	1’098.50	2.38 %	K V
ABB	45.05	1.65 %	K V
Alcon	79.56	1.61 %	K V
UBS Group	25.77	1.34 %	K V
Lonza Grp	571.20	-1.14 %	K V
Nestle	87.06	-1.24 %	K V
Swiss Re	149.15	-1.68 %	K V
Zurich Insur Gr	583.00	-1.72 %	K V
Roche Hldg G	259.90	-2.37 %	K V

mehr

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Simulations Plus Aktie VALOR 660020 / ISIN US8292141053

Nachrichten zu Simulations Plus IncShs

Aktien Top/Flop

Meistgelesene Nachrichten